ECSP12011584A - Anticuerpos anti-vegf y sus usos - Google Patents

Anticuerpos anti-vegf y sus usos

Info

Publication number
ECSP12011584A
ECSP12011584A ECSP12011584A ECSP12011584A EC SP12011584 A ECSP12011584 A EC SP12011584A EC SP12011584 A ECSP12011584 A EC SP12011584A EC SP12011584 A ECSP12011584 A EC SP12011584A
Authority
EC
Ecuador
Prior art keywords
vegf antibodies
vegf
antibodies
overproduction
activity
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Fiona Harding
Yoshiko Akamatsu
Robert B Dubridge
David B Powers
Original Assignee
Abbott Biotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42543312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011584(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Biotherapeutics filed Critical Abbott Biotherapeutics
Publication of ECSP12011584A publication Critical patent/ECSP12011584A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
ECSP12011584 2009-06-17 2012-01-09 Anticuerpos anti-vegf y sus usos ECSP12011584A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21800509P 2009-06-17 2009-06-17

Publications (1)

Publication Number Publication Date
ECSP12011584A true ECSP12011584A (es) 2012-08-31

Family

ID=42543312

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011584 ECSP12011584A (es) 2009-06-17 2012-01-09 Anticuerpos anti-vegf y sus usos

Country Status (26)

Country Link
US (1) US9079953B2 (OSRAM)
EP (2) EP2443150B1 (OSRAM)
JP (1) JP5785941B2 (OSRAM)
KR (1) KR20120034739A (OSRAM)
CN (1) CN102482349B (OSRAM)
AU (1) AU2010262836B2 (OSRAM)
BR (1) BRPI1012321A8 (OSRAM)
CA (1) CA2765755C (OSRAM)
CL (1) CL2011003182A1 (OSRAM)
CO (1) CO6480962A2 (OSRAM)
CR (1) CR20110653A (OSRAM)
EC (1) ECSP12011584A (OSRAM)
ES (2) ES2534355T3 (OSRAM)
GT (1) GT201100326A (OSRAM)
HK (1) HK1211961A1 (OSRAM)
IL (2) IL216835A0 (OSRAM)
MX (2) MX346002B (OSRAM)
NZ (1) NZ596837A (OSRAM)
PE (1) PE20120622A1 (OSRAM)
PH (1) PH12011502602A1 (OSRAM)
RU (1) RU2567639C2 (OSRAM)
SG (2) SG177265A1 (OSRAM)
TW (1) TWI510248B (OSRAM)
UA (1) UA104626C2 (OSRAM)
WO (1) WO2010148223A2 (OSRAM)
ZA (1) ZA201109098B (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
JP2014505698A (ja) * 2011-02-02 2014-03-06 グラクソ グループ リミテッド 新規抗原結合タンパク質
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US9605250B2 (en) * 2011-04-12 2017-03-28 Gangagen, Inc. Chimeric antibacterial polypeptides
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
HRP20190060T1 (hr) 2012-09-19 2019-02-22 F. Hoffmann - La Roche Ag Postupci i sastavi za sprečavanje pogrešne ugradnje norleukina u proteine
US9777067B2 (en) 2012-09-27 2017-10-03 Massachusetts Institute Of Technology HER2- and VEGF-A-binding proteins with enhanced stability
KR101279895B1 (ko) * 2012-10-24 2013-06-28 주식회사 진흥기공 유체 이송용 덕트에 결합 사용되는 댐퍼의 이중 브레이드 밀폐 장치
US20140154255A1 (en) * 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
CN105188749B (zh) 2012-12-21 2017-12-19 西雅图基因公司 抗ntb‑a抗体及相关组合物和方法
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
RU2646098C2 (ru) * 2013-04-30 2018-03-01 Интас Фармасьютикалс Лтд Новый способ клонирования, экспрессии и очистки для получения ранибизумаба
SG11201510315TA (en) * 2013-07-12 2016-01-28 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
WO2015164723A1 (en) * 2014-04-25 2015-10-29 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI719939B (zh) 2014-07-14 2021-03-01 日商中外製藥股份有限公司 鑑定蛋白質抗原決定位之方法
WO2016061562A2 (en) 2014-10-17 2016-04-21 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
CN108148134B (zh) * 2015-01-06 2020-06-12 珠海亿胜生物制药有限公司 抗vegf抗体
JP7088454B2 (ja) * 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
KR20190003556A (ko) * 2016-04-15 2019-01-09 리젠엑스바이오 인크. 완전히-인간형의 번역후 변형된 항-VEGF Fab를 이용한 눈 질환의 치료
IL322403A (en) * 2016-04-15 2025-09-01 Univ Pennsylvania Preparations for the treatment of wet age-related macular degeneration
CN106039309B (zh) * 2016-06-30 2024-04-19 中国人民解放军总医院第一附属医院 用于治疗恶性肿瘤造成的胸腔积液的药物组合物及其应用
RU2656160C2 (ru) 2016-08-17 2018-05-31 Закрытое Акционерное Общество "Биокад" Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека
AU2018342094B2 (en) * 2017-09-27 2025-02-06 Regenxbio Inc. Treatment of ocular diseases with fully-human post-translationally modified anti-VEGF Fab
MY207644A (en) 2017-12-19 2025-03-07 Akouos Inc Aav-mediated delivery of therapeutic antibodies to the inner ear
US20210093734A1 (en) * 2018-02-20 2021-04-01 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-realted macular degeneration
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
US20200115443A1 (en) * 2018-10-12 2020-04-16 Trican Biotechnology Co., Ltd Bi-functional fusion proteins and uses thereof
CN111423512B (zh) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN111363038A (zh) * 2020-03-26 2020-07-03 北京纽安博生物技术有限公司 抗VEGF单域抗体及其人源化、单域抗体和IgG1-Fc构建的融合蛋白和应用
CN111808191A (zh) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 一种用于检测血清中vegf含量的抗体对及其用途
US20240067711A1 (en) * 2020-08-31 2024-02-29 Medytox Inc. Anti-vegf hexameric antibody and composition comprising same
MX2023006451A (es) 2020-12-01 2023-06-15 Akouos Inc Construcciones de anticuerpos anti-vegf y metodos relacionados para el tratamiento de los sintomas asociados al schwannoma vestibular.
WO2022183418A1 (zh) * 2021-03-04 2022-09-09 百奥泰生物制药股份有限公司 抗vegf抗体制剂
WO2023150142A1 (en) 2022-02-02 2023-08-10 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
CN120248142B (zh) * 2025-06-06 2025-09-12 上海兴瑞一达生物科技有限公司 一种共表达cd47和il-15的双靶点嵌合抗原受体、car-t细胞及其应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP1695985B1 (en) 1997-04-07 2011-03-09 Genentech, Inc. Methods for forming humanised antibodies by random mutagenesis
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP2002530081A (ja) 1998-11-18 2002-09-17 ジェネンテック・インコーポレーテッド 親抗体より高度な結合親和性を持つ抗体変異体
EP1950300A3 (en) 1998-11-18 2011-03-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
ATE300957T1 (de) 1998-12-22 2005-08-15 Genentech Inc Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
US6979559B2 (en) 2000-10-12 2005-12-27 Marical, Inc. Polyvalent cation-sensing receptor in atlantic salmon
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
JP4309656B2 (ja) 2000-12-14 2009-08-05 ジェネンテック・インコーポレーテッド 原核生物で生成させた抗体とその用途
US6828121B2 (en) 2000-12-14 2004-12-07 Genentech, Inc. Bacterial host strains
CA2369893A1 (en) 2001-02-12 2002-08-12 Warner-Lambert Company Vegf responsive cell-based assay for determining vegf bioactivity
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US20030022240A1 (en) 2001-04-17 2003-01-30 Peizhi Luo Generation and affinity maturation of antibody library in silico
US20040010376A1 (en) 2001-04-17 2004-01-15 Peizhi Luo Generation and selection of protein library in silico
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030224397A1 (en) 2002-02-11 2003-12-04 Genentech, Inc. Antibody variants with faster antigen association rates
SG135053A1 (en) * 2002-05-20 2007-09-28 Abmaxis Inc Generation and selection of protein library in silico
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7608429B2 (en) 2002-10-31 2009-10-27 Genentech, Inc. Methods and compositions for increasing antibody production
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US20050186208A1 (en) 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
CA2531595C (en) 2003-07-28 2015-12-08 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2006031370A2 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
CA2583937A1 (en) 2004-10-12 2006-04-27 Amprotein Corporation Chimeric protein
MX2007004374A (es) 2004-10-12 2008-01-29 Amprotein Corp Proteina quimerica.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US20080207467A1 (en) 2005-03-03 2008-08-28 Xencor, Inc. Methods for the design of libraries of protein variants
US8716195B2 (en) 2005-11-14 2014-05-06 Bioren, Inc. Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
WO2007059336A1 (en) 2005-11-18 2007-05-24 Nextrom Oy Method and apparatus for manufacturing water-free optical fiber preforms
WO2007062037A2 (en) 2005-11-21 2007-05-31 Laboratoires Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
US20080015194A1 (en) 2006-01-23 2008-01-17 Joseph Errico Methods and compositions of targeted drug development
CA2658241C (en) 2006-07-10 2018-01-02 Esbatech Ag Scfv antibodies which pass epithelial and/or endothelial layers
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
CA3113365A1 (en) 2007-07-09 2009-01-15 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
EP2280997A2 (en) 2008-04-18 2011-02-09 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions

Also Published As

Publication number Publication date
HK1211961A1 (en) 2016-06-03
BRPI1012321A2 (pt) 2016-03-15
NZ596837A (en) 2014-02-28
PH12011502602A1 (en) 2012-11-12
WO2010148223A3 (en) 2011-03-03
CL2011003182A1 (es) 2012-07-20
US9079953B2 (en) 2015-07-14
AU2010262836A1 (en) 2011-12-22
CA2765755C (en) 2018-01-02
IL239604A (en) 2016-08-31
CA2765755A1 (en) 2010-12-23
SG177265A1 (en) 2012-02-28
CR20110653A (es) 2012-05-08
ES2534355T3 (es) 2015-04-21
ES2656446T3 (es) 2018-02-27
CO6480962A2 (es) 2012-07-16
GT201100326A (es) 2013-01-24
CN102482349A (zh) 2012-05-30
CN102482349B (zh) 2017-08-25
KR20120034739A (ko) 2012-04-12
EP2443150B1 (en) 2015-01-21
UA104626C2 (ru) 2014-02-25
US20100322931A1 (en) 2010-12-23
JP2012530496A (ja) 2012-12-06
JP5785941B2 (ja) 2015-09-30
RU2011150916A (ru) 2013-07-27
EP2443150A2 (en) 2012-04-25
EP2894167A1 (en) 2015-07-15
ZA201109098B (en) 2012-08-29
TWI510248B (zh) 2015-12-01
IL239604A0 (en) 2015-08-31
RU2567639C2 (ru) 2015-11-10
PE20120622A1 (es) 2012-05-26
TW201103561A (en) 2011-02-01
MX2011013781A (es) 2012-05-29
BRPI1012321A8 (pt) 2016-09-27
MX346002B (es) 2017-03-01
SG10201403327WA (en) 2014-10-30
EP2894167B1 (en) 2017-11-08
WO2010148223A2 (en) 2010-12-23
AU2010262836B2 (en) 2015-05-28
IL216835A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
ECSP12011584A (es) Anticuerpos anti-vegf y sus usos
ECSP11011450A (es) ANTICUERPOS ANTI-TNF-a Y SUS USOS
BR112015012538A2 (pt) anticorpos anti-vegf e seus usos
JO3182B1 (ar) مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
GT201200058A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CO6630087A2 (es) Anticuerpos bivalentes biespecificos anti-vegf/anti-ang-2
ECSP12012017A (es) DERIVADOS DE SULFONAMIDA COMO AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CÁNCER Y ENFERMEDADES INMUNES
UY31862A (es) Inmunoglobulina con dominio variable dual y usos de la misma
CO6930356A2 (es) Compuestos inhibidores de metaloenzimas
GT201200109A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
WO2010093954A3 (en) Control of plant stress tolerance, water use efficiency and gene expression using novel aba receptor proteins and synthetic agonists
UY33575A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UY30525A1 (es) Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos
MA37506B1 (fr) Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
UA107836C2 (uk) Метод лікування хвороби альцгеймера
GT201100300A (es) Piperidinas sustituidas
NZ609501A (en) Antibodies to notum pectinacetylesterase
BR102012013982A2 (pt) 5-fluorocitosina como um tratamento de semente
EP2427556A4 (en) INCREASED PROTEIN PRODUCTION BY INCREASING EXPRESSION OR BZW. EFFECT OF ABC50
MX2010000823A (es) Metodo para eliminar enfermedades de plantas.
UA110226C2 (en) Antibodies to cd38
UA112521C2 (uk) Антитіло проти gdf8 людини
TH148737A (th) สารยับยั้งสเต็มเซลล์แฟคเตอร์